TickerKhojComparison · NSE · data 2026-11-02
Cohance Lifesciences Ltd vs Eris Lifesciences Ltd
In plain words
Size: Cohance Lifesciences Ltd is about 1.1 times the market value of Eris Lifesciences Ltd.
Valuation (P/E): Cohance Lifesciences Ltd 161.5 vs Eris Lifesciences Ltd 23.1.
Return on equity: Eris Lifesciences Ltd 18.3% vs Cohance Lifesciences Ltd 6.4%.
Profit growth over 3 years: Eris Lifesciences Ltd 17.5% a year vs Cohance Lifesciences Ltd -24.2% a year.
Debt to equity: Eris Lifesciences Ltd 0.6 vs Cohance Lifesciences Ltd 0.1.
Differences in the numbers, not a recommendation of either stock.
Side by side
| COHANCE | ERIS | |
|---|---|---|
| Price | ₹445.7 | ₹1,184.4 |
| Market cap | ₹17,005 cr | ₹16,088 cr |
| P/E | 161.5 | 23.1 |
| P/B | 4.4 | 4 |
| ROE | 6.4% | 18.3% |
| ROCE | 4.6% | 15.6% |
| Debt / equity | 0.1 | 0.6 |
| Operating margin | 5.8% | 26.3% |
| Dividend yield | 0.00% | 0.62% |
| Sales growth, 3 years (yearly) | 19.0% | 22.9% |
| Profit growth, 3 years (yearly) | -24.2% | 17.5% |
| 1-year return | -42.8% | -27.2% |
| Revenue, last 12 months | ₹2,142 cr | ₹3,330 cr |
| Net profit, last 12 months | ₹106 cr | ₹708 cr |
| Latest quarter | Jun 2026 | Sept 2026 |
| Quarter net profit | ₹-24 cr | ₹184 cr |
| Quarter profit vs a year earlier | -149.3% | +52.9% |
| Promoter holding | 57.48% | 54.74% |
| Health check | Weak (2.2/10) | Strong (7/10) |
Common questions
Which has a higher P/E, Cohance Lifesciences Ltd or Eris Lifesciences Ltd?
Cohance Lifesciences Ltd trades at the higher P/E (161.5 against 23.1). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Eris Lifesciences Ltd (18.3% against 6.4%).
Which carries more debt?
Eris Lifesciences Ltd has the higher debt-to-equity ratio (0.6 against 0.1).